In the second half of 2021 the number of debt offerings decreased significantly by 37.5% from the same period in 2020.
But this actually marks an acceleration in growth from the 67.7% decrease in deals that occurred in H1 2021 relative to the same period a year earlier.
During second half of 2021, debt offerings accounted for 5.5% of all deals taking place in the sector. This represents a decrease from the figure of 7% in second half of 2020.
GlobalData's deals database is a comprehensive repository that looks at mergers, acquisitions, venture financing, equity offerings, asset transactions, partnerships and debt offerings taking place daily between thousands of companies across the world.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The database details key deal information, such as deal summary, deal rationale, deal financials, parties involved, advisors and deal payment modes.
By tracking the proportion of various types of deals in each sector we can gauge which sectors are seeing growth and where others are struggling.
The highest value debt offering announced in 2021 (where the deal value was known), is the funds to be raised by Takeda Pharma in a public offering of 0.400% senior bonds due in 2031.
The debt offering is set to be worth $2242.5 million.
The database states that the rationale behind this deal was as follows: "Takeda intends to use the proceeds primarily to prepay borrowings of USD1.7 billion that remain outstanding on a term loan incurred in connection with the acquisition of Shire plc in 2019 and which has an original maturity date of December 2025. The remaining bond issuance proceeds, will be used for the redemption of bonds or be deployed towards the working capital needs."